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Abstract 
Oral sustained release drug delivery system is being widely used for the past two decades 
as a means to provide a drug with improved therapeutic efficacy and also to assure 
rational drug therapy. The sustained release dosage form allows slow release of the drug 
followed by the maintenance of a constant therapeutic blood or tissue drug levels for an 
extended period of time. This characteristic of the dosage form further decreases 
frequency of drug intake ensuring better patient compliance and often reduces adverse 
effects associated with drug. The aim of the present study was to design and develop an 
optimized once daily oral sustained release matrix tablet formulation of a potent non-
steroidal anti-inflammatory drug (NSAID), Ketorolac Tromethamine. Ketorolac 
Tromethamine has a short biological half-life of 4 to 6 hours, so it was considered as a 
suitable drug for the formulation of sustained release tablet to prolong its therapeutic 
action and reduce dosing frequency. The experiment was designed to develop nine 
different formulations of matrix tablets by using combination of hydrophilic Methocel 
K100M CR and Methocel K4M CR polymers at different ratios. The selection of the 
excipients was based on IR and DSC studies depending on the compatibility of which the 
tablets were manufactured by direct compression. The resulting tablets were evaluated 
for physical properties such as weight variation, hardness, thickness, friability and drug 
content which complied with the limits specified in USP. In vitro dissolution study was 
performed in order to obtain the drug release profile of the matrix tablets and the 
outcomes were fitted into various mathematical models for release kinetic analysis. Most 
of the formulated tablets were found to follow Higuchi drug release kinetics and 
exhibited non-Fickian type drug release mechanism. Furthermore, in order to obtain an 
optimum product, a 32 full factorial design was employed to systematically optimize the 
drug release profile with Design Expert software. The analysis of the responses produced 
by the software revealed that the polymer combination used at different ratios has control 
on the drug release. F4 was selected as the optimum formulation significantly on the 
basis of desirability criterion and graphical analysis.    
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Introduction 
Oral drug delivery system is considered to be the most convenient route of drug 
administration. There are several techniques by which such drugs can be designed based 
on some interrelated variables such as type of delivery system, the disease being treated, 
the patient, the length of therapy and physicochemical properties of drug (Etman et al., 
2008). A conventional dosage form of the drug usually do not maintain the therapeutic 
range of plasma drug level for extended period of time and often require multiple-dose 
therapy. This approach of repetitive dosing, however, exhibits some drawbacks such as 
frequent administration especially for drugs with short biological half-life, patient non-
compliance with multiple dosage regimens and sometimes, under medication or over 
medication at certain disease states (Gennaro, 2000). 
In order to minimize these limitations of a conventional dosage form, oral sustained 
release drug delivery system is being widely used for the past two decades as a means to 
provide a drug with improved therapeutic efficacy and also to assure rational drug 
therapy. The sustained release dosage form allows slow release of the drug followed by 
the maintenance of a constant therapeutic blood or tissue drug levels for an extended 
period of time (Figure 1.1). Further benefits of this drug delivery system include 
reduction in dose frequency and adverse side effects, increase in patient compliance, 
better therapeutic performance and even reduced healthcare cost when compared with 
that of conventional dosage form. Overall, administration of sustained release dosage 
form enables increased reliability of therapy eliminating the potential threat for both 
under and over dosing (Etman et al., 2008). 
 
Introduction 
2 
 
 
Figure 1.1: Comparison of conventional and sustained release profiles 
 
There are several methods by which a sustained release tablet can be manufactured and 
the selection of the manufacturing process depends on the physicochemical properties of 
the components used in the formulation. A relatively easier and cost effective approach 
to the manufacture of the dosage form involves the direct compression of the mixture of 
drug, polymer and excipients to form a tablet in which the drug is embedded in a matrix 
core of the retardant. Alternatively, granulation of the mixture can be done prior to 
compression if required (Bose, Wong, & Singh, 2013). 
The present study involves the formulation of sustained release matrix tablet of a non-
steroidal anti-inflammatory drug (NSAID), Ketorolac Tromethamine through the use of 
different grades of natural hydrophilic polymers at various combinations which is 
eventually followed by release kinetic study and optimization of formulation so that a 
once daily sustained release tablet formulation could be obtained. 
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Figure 1.2: Flowchart of the study design of the project 
 
1.1 Rationale of the study: 
It is well recognized that a drug with a short half-life may be eliminated from the body at 
a faster rate resulting in a plasma level concentration insufficient to produce therapeutic 
effect. On the other hand, the development of the sustained release dosage form 
maintains constant therapeutic blood or tissue drug level for an extended period of time 
through prolongation of drug release. Therefore, such modified release drug delivery 
system is considered to be the most convenient mode of drug administration which can 
be achieved through the formation of a matrix system. In this system, the rate and the 
mechanism of drug release is controlled by the type and concentration of polymers used 
in the tablet formulation. There are four types of matrix system that can be used to design 
the sustained release dosage form which includes matrix composed of insoluble inert 
polymer, insoluble erodible polymer, hydrophilic polymer or hydrogel polymer. A 
hydrophilic polymer matrix system is widely used to prolong the drug release because of 
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its ability to undergo rapid hydration, good compression and gel forming characteristics, 
easy availability and cost effectiveness (Diwedi, Alexander, & Chandrasekar, 2011). It is 
a dynamic system which is dependent on polymer wetting, hydration, gel formation, 
swelling and dissolution. Simultaneously, the water soluble component of the tablet 
diffuses through the tablet core while the insoluble materials are released through tablet 
erosion as shown in Figure 1.3 (DOW, 2006).  
 
Figure 1.3: Drug release from a hydrophilic matrix tablet 
Ketorolac Tromethamine (KT) is commercially available as immediate release oral tablet 
dosage form. It has a short biological half-life of 4 to 6 hours which makes it susceptible 
to frequent administration per day to maintain the therapeutic effect. This multiple 
dosing regimen often leads to gastrointestinal (GI) adverse effects such as GI bleeding, 
GI perforation or peptic ulcer. Hence, the sustained release formulation of this drug can 
be thought of as a most suitable method to minimize GI side effects, reduce dosing 
frequency and increase patient compliance (El-Gizawy, Zein El Din, Donia, & Yassin, 
2014). Moreover, since the dosage regimen of conventional tablet of Ketorolac 
Tromethamine is 10mg every 4 to 6 hours i.e. 3 to 4 times a day due to its short half-life, 
a once daily sustained release form of the drug can overcome the problems associated 
with increased dose frequency, patient incompliance and adverse GI effects. In addition, 
KT has a similar potency as an analgesic to that of opioids often used for post-operative 
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pain relief. Therefore, intake of KT spares the patient from the adverse effects of opioids 
which includes respiratory depression, psychomotor disturbances, ataxia, sedation, 
constipation, tolerance, and dependence (Vadivelu et al., 2015). So, the successful 
formulation of a sustained release dosage form of KT may be potentially beneficial to the 
patient‟s health. 
In this study of sustained release oral tablet formulation development of KT, 
compatibility study of the drug with each excipient was performed by Fourier Transform 
Infrared Radiation (FT-IR) to support product development and justify the use of the 
selected excipients. Further confirmation of compatibility was conducted by a thermo 
analytical technique known as Differential Scanning Calorimetry (DSC) study. This led 
to direct compression of the powder blend into tablet followed by in vitro dissolution of 
the tablet whose results were analyzed and deployed to obtain once daily optimum 
formulation of KT.  
 
1.2 Drug profile: 
Ketorolac Tromethamine: 
Ketorolac Tromethamine (KT) is a potent non-steroidal anti-inflammatory drug (NSAID) 
that belongs to the pyrrolizine group. It was the first NSAID commercialized in the 
United States for parenteral use in 1990 and later was approved by the FDA for 
administration as an immediate release oral tablet in 1991. Currently, it is available as 
oral, intramuscular, intravenous, ophthalmic dosage form. KT shows potent analgesic 
and mild anti-inflammatory activity in the treatment of moderate to severe acute pain by 
inhibiting the action of cyclooxygenase enzyme responsible for prostaglandin synthesis. 
Ketorolac Tromethamine is a racemic mixture of [-S] and [+R] enantiomeric forms, with 
the S-form having analgesic activity (Vadivelu et al., 2015). 
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1.3 Literature review: 
Extensive literature review was initially done to select the drug, polymer, excipients, 
solvent, experimental conditions along with the study of release kinetic models and 
method of optimization to formulate oral sustained release matrix tablet of Ketorolac 
Tromethamine. Following are the list of journals that were searched for the present 
study: 
1. Journal of Applied Pharmaceutical Science 
2. International Journal of Pharmaceutical Science and Research 
3. Bangladesh Journal of Scientific and Industrial Research  
4. Acta Poloniae Pharmaceutica-Drug Research 
5. International Journal of Pharmaceutical Research and Bio-science 
6. Asian Journal of Pharmaceutical and Clinical Research 
7. Pakistan Journal of Pharmaceutical Sciences 
8. Saudi Pharmaceutical Journal 
9. World Journal of Pharmaceutical Sciences 
10. International Journal of Pharmacy and Pharmaceutical Sciences 
11. Dhaka University Journal of Pharmaceutical Science 
12. Asian Journal of Pharmaceutical Sciences 
13. Advanced Drug Delivery Reviews 
14. Journal of Analytical and Bioanalytical Techniques 
15. Advanced Drug Delivery Reviews 
16. American Journal of drug delivery 
17. Journal of Thermal Analysis and Calorimetry 
18. Pain Practice 
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Methodology 
The research methodology of this project has been developed based on a proposed 
sustained release formulation of Ketorolac Tromethamine. In the study, Ketorolac 
Tromethamine, a member of NSAID has been amalgamated with Methocel K100M CR 
and Methocel K4M CR of different ratios to form matrix tablets. Excipients chosen for 
the formulation have been subjected to compatibility study and their compatibility with 
the active ingredient has been verified. The proposed formula of the sustained release 
tablet of Ketorolac Tromethamine is given in Table 2.1. 
Table 2.1: Proposed formula of the drug 
Active Pharmaceutical Ingredient Amount 
Ketorolac Tromethamine 30mg 
Excipients Justification (of use) 
Methocel K100M CR Rate controlling polymer 
Methocel K4M CR Rate controlling polymer 
Starch 1500 Binder 
Avicel PH 101 Filler 
Magnesium stearate  Lubricant 
Talc Glidant 
 
2.1 Standardization of Ketorolac Tromethamine by UV-Visible spectrophotometer: 
10mg of Ketorolac Tromethamine was accurately weighed and dissolved in100ml of 
distilled water to obtain a concentration of 100µg/ml. From the above mixture 8ml, 9ml, 
10ml, 11ml and 12ml solution was withdrawn and diluted to 100ml to obtain 
concentrations in the range 8.4µg/ml to 12.6µg/ml respectively. This was followed by 
the measurement of absorbance with UV-Visible spectrophotometer for each 
concentration at 322nm (Table 3.1). 
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2.2 Drug-Excipient compatibility study: 
A formulation is considered appropriate when no interactions between drug-excipient 
and excipient-excipient occur. The evaluation of drug-excipient compatibility is an 
essential part in the development of any stable dosage form as incompatibility between 
drug and excipients can lead to the alteration of absorption and bioavailability of the 
drug, thereby, affecting the stability, safety and/ or efficacy of the drug delivery system 
(Gupta & Chadha, 2015). So during the development of dosage form various excipients 
are studied for compatibility with API. FT-IR spectroscopy and DSC are frequently 
employed as a rapid method to ascertain any possible interaction between the 
formulation components and therefore facilitate the selection of excipients with suitable 
compatibility.   
2.2.1 FT-IR study: 
FT-IR, Fourier Transform Infrared spectroscopy is the study of the interaction of 
electromagnetic radiation from the IR region of the EM spectrum (4000-400) cm-1 with a 
molecule through which IR radiation is passed. The nature of interaction depends upon 
the functional groups present in the substance. Compounds of different structure usually 
exhibit different IR spectrum. Any interaction between the drug and the excipient may 
lead to change in the molecular structure thereby generating a different IR spectrum to 
that of the pure drug and hence, indicates incompatibility. For the purpose of drug-
excipient compatibility test by FT-IR, six FT-IR test samples were prepared by mixing 
each drug entities separately with the individual excipient in the ratio of 1:1. The pure 
Ketorolac Tromethamine was also passed through FT-IR for reference. The IR spectrum 
obtained for each prepared sample within 4000-400cm-1 region was recorded and studied 
for any interaction between the drug and the excipients. The tests were designed in 1:1 
ratio as follows: 
1. Ketorolac Tromethamine + Methocel K100M CR 
2. Ketorolac Tromethamine + Methocel K4M CR 
3. Ketorolac Tromethamine + Starch 1500 
4. Ketorolac Tromethamine + Avicel PH101 
5. Ketorolac Tromethamine + Magnesium stearate 
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6. Ketorolac Tromethamine + Talc 
2.2.2 DSC study: 
The samples for DSC, Differential Scanning Calorimetry analysis were prepared in 1:1 
ratio with the same composition as for FT-IR. In DSC analysis, DSC curves were 
obtained for the pure drug and drug with each of the excipients by placing 3mg of the 
sample into a disc followed by its insertion inside the machine. The samples were run 
under nitrogen atmosphere at a flow rate of 30ml/min and a heating rate of 10°C in the 
temperature range 30-300°C.  
 
2.3 Evaluation of powder flow properties: 
The powder blends prepared for compression into sustained release tablets were 
evaluated for their compressibility and flow properties. 
2.3.1 Bulk density: 
The loose bulk density (LBD) and tapped bulk density (TBD) of the powder for each 
proposed formulation were determined by taking a quantity of about 10gm of powder 
from each formulation into a 100ml measuring cylinder. After the initial volume of the 
powder was noted, the cylinder was allowed to tap several times until no further change 
in the volume was observed. LBD and TBD were calculated by using the following 
formulae:  
    
                    
                          
 
     
                    
                           
 
2.3.2 Carr’s index and Hausner ratio: 
Carr‟s Index and Hausner ratio were calculated from bulk density to determine the flow 
and compressibility characteristics of the powder blend as given in the formulae below: 
             ( )   
(       )     
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Table 2.2: Relationship between Carr’s index and powder flow  
Carr’s index Type of flow 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
> 40 Extremely poor 
Source: Aulton, 2002 
 
Table 2.3: Relationship between Hausner ratio and powder flow  
Hausner ratio Powder flow 
< 1.25 Good 
1.25-1.5 Fair to passable 
>1.5 Poor 
Source: Aulton, 2002 
 
2.3.3 Angle of repose: 
The angle of repose of the powder was determined for each proposed formulation by the 
funnel method. In this method, the powder was allowed to flow through the funnel 
clamped at a fixed height (h) of 3cm, until the apex of the heap of powder just touched 
the tip of the funnel. The diameter of the powder cone was measured and angle of repose 
was calculated using the following equation:  
     
 
 
 
where, h = height of the powder cone,  r= radius of the powder cone, Ø = angle of repose 
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Table 2.4: Relationship between angle of repose and powder flow properties  
Angle of repose Type of flow 
<20 Excellent 
20-30 Good 
30-34 Passable 
>40 Very poor 
 Source: Aulton, 2002 
 
2.3.4 Moisture content:   
The presence of moisture in the powder affect its flow characteristics as the particles 
become cohesive due to moisture absorption and often the powder shows poor 
flowability. So the powder blend of each formulation was subjected to drying in oven 
and also its moisture content was determined with the moisture analyzer prior to 
evaluation of the flow properties of the powder. 
 
2.4 Polymer combination of matrix tablet formulations using 32 full factorial 
design: 
A 32 randomized full factorial design was used in the present study. In this design, 2 
factors were evaluated, each at 3 levels (low, mid and high), and experimental trials were 
performed for all 9 possible combinations. The amounts of Methocel K100M CR (A) 
and Methocel K4M CR (B) were selected as independent variables in 32 full factorial 
design while the percentage of drug released from tablets of different polymer ratio were 
taken as dependent variables (Bushra, Shoaib, Aslam, Hashmat, & Rahman, 2008). The 
32 full factorial design layout for the trial batches (F1-F9) is shown in Table 2.5 and 2.6. 
Table 2.5: 32 full factorial design layout 
Coded value Actual values 
A (%) B (%) 
-1 (low level) 30 5 
0 (mid level) 35 7.5 
+1 (high level) 40 10 
A and B indicates the amount of Methocel K100M and Methocel K4M respectively 
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Table 2.6: Polymer combinations of formulation (F1-F9) 
Formulation Batch Code K100M:K4M 
(%) 
 
A B 
F1 -1 -1 30 5 
F2 -1 0 30 7.5 
F3 -1 +1 30 10 
F4 0 -1 35 5 
F5 0 0 35 7.5 
F6 0 +1 35 10 
F7 +1 -1 40 5 
F8 +1 0 40 7.5 
F9 +1 +1 40 10 
 
 
2.5 Preparation of matrix tablets: 
Drug, polymer and excipients were weighed separately for 15 tablets for each 
formulation as shown in Table 2.7. The proposed formulations were coded as F1, F2, F3, 
F4, F5, F6, F7, F8 and F9. After weighing, polymer and excipients for each formulation 
were mixed thoroughly followed by the addition of the API with further mixing to ensure 
homogenous distribution of the particles. The powder mixture of each formulation was 
passed through a 40 mesh sieve. The sieved mass was poured in the hopper of the tablet 
compression machine and the die and punch were adjusted to get the desired weight of 
the tablet (300 mg). Finally, the weights and hardness of the resulting tablets per 
formulation were checked.  
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Table 2.7: Formulation of Ketorolac Tromethamine sustained release matrix tablets 
Components Amount (%) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Ketorolac 
Tromethamine 
10 10 10 10 10 10 10 10 10 
Methocel K100M CR 30 30 30 35 35 35 40 40 40 
Methocel K4M CR 5 7.5 10 5 7.5 10 5 7.5 10 
Starch 1500 26.5 25.25 24 24 22.75 21.5 21.5 20.25 19 
Avicel PH 101 26.5 25.25 24 24 22.75 21.5 21.5 20.25 19 
Magnesium stearate  1 1 1 1 1 1 1 1 1 
Talc 1 1 1 1 1 1 1 1 1 
Total 100 
 
2.6 Evaluation of physical properties of matrix tablets: 
The matrix tablets manufactured was assessed for quality control parameters to ensure its 
compliance with pharmacopoeial specifications. 
2.6.1 Weight variation: 
To determine the weight variation among tablets, 10 tablets for each matrix formulation 
were weighed individually using the electronic balance and the average weight of the 10 
tablets was calculated.  Then the percentage of weight variation was determined by using 
the following formula: 
                   
(                              )     
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Table 2.8: Pharmacopeial specifications for tablet weight variation 
 
 
 
 
 
               Source: Lieberman & Kanig, 1986   
 
2.6.2 Tablet hardness: 
The hardness of the tablets for each formulation was determined by applying a diametric 
compression force on the tablets with the hardness tester.  
 
2.6.3 Tablet friability: 
The initial weight of five tablets for each proposed formulation was measured and then 
the tablets were allowed to rotate in a friabilator at 100 rpm for 4 minutes. The tablets 
were dedusted and reweighed. Percentage friability was calculated from the loss in 
weight as given in the equation below: 
             
(                                             )     
                       
 
The United State Pharmacopoeia states that the friability value of tablets should be less 
than 1% (Nasrin, Asaduzzaman, Mowla, Rizwan, & Alam, 2011). 
 
2.6.4 Tablet thickness and diameter: 
The thickness and diameter of six randomly selected matrix tablets were determined 
using a vernier caliper. 
 
2.6.5 Tablet drug content: 
To prepare the standard solution of Ketorolac Tromethamine, 30mg of the drug was 
dissolved in distilled water upto the volume of 100ml. The solution was diluted 10 times 
and absorbance was taken at λmax= 322nm. For the purpose of sample solution 
preparation, three tablets were crushed using motor and pestle. The powder weight 
equivalent to single tablet was dissolved in distilled water and the volume was made upto 
100ml. This solution also went through 10 times dilution followed by measurement of 
Average weight of tablets (mg) 
(USP) 
Maximum % difference 
Less than 130 10 
130-324 7.5 
More than 324 5 
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absorbance at λmax= 322nm. Then the drug content per dosage unit was calculated by the 
following equation: 
Ketorolac Tromethamine content (mg / dosage unit), 
 
                                                       
                                        
 
 
2.7 In vitro dissolution study: 
Dissolution testing plays an important role in the drug formulation development 
especially in the establishment of in vitro–in vivo relationships between release of drug 
from the dosage form and drug absorption. Furthermore, the physicochemical properties 
of the drug, excipients used or their combination as well as manufacturing conditions 
selected to prepare the tablet influences the dissolution rate from a tablet (Etman et al., 
2008). 
2.7.1 Preparation of dissolution medium: 
To prepare phosphate buffer of pH 6.8, 6.8gm potassium hydrogen phosphate (KH2PO4) 
and 0.94gm sodium hydroxide (NaOH) were dissolved in distilled water to make the 
volume upto 1000ml. The pH of the solution was adjusted by using dilute 
orthophosphoric acid or NaOH as required. 
2.7.2 Preparation of the sample for dissolution: 
900ml phosphate buffer dissolution medium was poured into the dissolution vessels. 
Then the media was allowed to warm to a temperature of 37°C ± 0.5°C. Three tablets of 
each of the 9 formulations were weighed and immersed into the media, which positioned 
itself between the paddle and the bottom of the vessel. The apparatus was operated at 
100 rpm and observed for 8 hours. Samples of about 5ml were withdrawn after 0.5, 1, 2, 
4 and 8 hours and same quantity was then replaced with fresh dissolution medium. 
Afterwards the collected samples were filtered through the filter paper and their 
absorbance was measured by UV-Visible spectrophotometer at 322nm. By using the 
absorbance reading and the standard curve equation of Ketorolac Tromethamine, the 
percentage of drug released from the matrix tablet of various polymer ratios was 
calculated. The following formulae were used for the calculation: 
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Equation of the standard curve: 
         Y = 52.19X + 0.0422 
Where, Y = Absorbance and X = Concentration (mg/ml) 
          X = Y- 0.0422/ 52.19 
          % drug release = X (mg/ml) × 900 (ml) × 100/ weight of API (mg)  
The release data were analyzed using different kinetic equations which include zero-
order, first-order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell models. 
 
2.8 In-vitro dissolution release kinetic study of matrix tablets: 
The drug release data obtained from in vitro dissolution of matrix tablets F1 to F9 for 8 
hours were fitted into various mathematical models to determine the release mechanism 
and find the model that best fits the drug release profile. For the drug release kinetic 
study, the models (Ahamed, Banik, & Hossain, 2013) that have been employed include: 
i. Zero order model: Cumulative percentage of drug release versus time.  
ii. First order model: Log cumulative percentage of drug remaining versus time.  
iii. Higuchi model: Cumulative percentage of drug release versus square root of 
time. 
iv. Korsmeyer-Peppas model: Log fraction of drug release versus log of time.  
v. Hixson-Crowell model: Cubic root of percentage drug release versus time. 
 
Mathematical equations that represent the release kinetics are described below: 
 
2.8.1 Zero order equation: 
The zero-order model describes the systems where the drug release rate is independent of 
its concentration. The equation assumes the cumulative amount of drug release versus 
time. The equation is as follows: 
         C = K0 t     [equation 1] 
where, C = drug concentration at „t‟ time 
            K0 = zero order rate constant expressed in unit concentration/time 
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             t = time in hour 
A graph of concentration against time would yield a straight line with a slope equal to K0 
and intercept the origin of the axes (Talukder, Ahmed, Haque, & Chowdhury, 2010). 
 
2.8.2 First order equation: 
The first order model describes the release from systems where the release rate is 
concentration dependent. The release behavior of first order equation is expressed as log 
cumulative percentage of drug remaining versus time (Talukder, Ahmed, Haque, & 
Chowdhury, 2010).The equation may be as follows: 
         log C = log C0– K t/ 2.303     [equation 2] 
where, C= amount of drug remaining at „t‟ time 
            C0 = drug concentration at t = 0 
            K = first order rate constant  
 
 2.8.3 Higuchi square root law: 
Higuchi model describes the release of drugs from an insoluble matrix as a square root of 
a time-dependent process based on Fickian diffusion. The Higuchi release model is 
described as cumulative percentage of drug release versus square root of time. The 
equation is as follows: 
          Q = Kh t 
½     [equation 3]  
where, Q = (100-C) i.e. the amount of drug released at time „t‟ 
            Kh = the constant reflecting the design variables of the system  
Hence, drug release rate is proportional to the reciprocal of the square root of time 
(Talukder, Ahmed, Haque, & Chowdhury, 2010). 
 
2.8.4 Korsmeyer-Peppas model: 
The Korsmeyer-Peppas model is generally used to analyze the release of a drug molecule 
from a polymeric matrix using the following equation: 
         log (Mt/Mf) = log K + n log t    [equation 4] 
where, Mt = amount of drug release at time „t‟ 
            Mf = amount of drug release after infinite time 
            K = release rate constant incorporating structural and geometric characteristics of 
the dosage form 
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             n = diffusional exponent indicative of the mechanism of drug release 
The log value of percentage drug dissolved is plotted against log time for each 
formulation according to the equation (Talukder, Ahmed, Haque, & Chowdhury, 2010). 
The process responsible for the drug release from the matrix tablet can be determined 
from the diffusional exponent (n) which is influenced by the shape of the tablet. Based 
on the „n‟ value of a spherical shaped tablet (Table 2.9), drug transport mechanism from 
the tablet is classified into four types (Siepmann & Peppas, 2001) which are as follows: 
i. Fickian (case I) diffusion: Diffusion-controlled drug release. 
ii. Case II transport: Drug release controlled by polymer relaxation.  
iii. Non-Fickian or anomalous transport: Both diffusion and erosion regulated 
drug release. 
iv. Super case II transport: Erosion-controlled drug release.  
 
Table 2.9: Diffusional exponent as an indicator of release mechanism 
Diffusional exponent (n) Mechanism of transport 
0.43 Fickian (case I ) diffusion 
0.43<n<0.85 Anomalous / non – Fickian transport 
0.85 Case II / Zero order transport 
>0.85 Super case II transport 
Source: Siepmann & Peppas, 2001 
 
2.8.5 Hixson-Crowell cube root law: 
It is the law that describes the release from systems where there is a change in surface 
area and diameter of the particles or tablets. This law is expressed as the cube root of the 
percentage of initial drug minus the cube root of the percentage of drug remaining in the 
matrix, as a function of time (Dash, Murthy, Nath, & Chowdhury, 2010). The equation is 
as follows: 
         Q0 
1/3 – Q t 1/3= KHC. t     [equation 5] 
  where, Q0 = initial amount of the drug in the tablets 
              Qt = the amount of drug remaining in time „t‟  
              KHC = rate constant for the Hixson-Crowell cube root law  
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2.9 Successive fractional dissolution time: 
To characterize the drug release rate in different experimental conditions, time required 
for 25% (T25%), 50% (T50%) and 80% (T80%) of drug release were calculated from 
dissolution data according to the following equations: 
      T25% = (0.25/K)
1/n 
      T50% = (0.5/K)
1/n 
      T80% = (0.8/K)
1/n 
Mean dissolution time (MDT) value is used to characterize the drug release rate from the 
dosage form and the retarding efficiency of the polymer. A higher drug retaining ability 
of the polymer is indicated by a higher MDT value and vice-versa. The MDT value is 
also a function of polymer loading, polymer nature and physicochemical properties of 
the drug molecule (Talukder, Ahmed, Haque, & Chowdhury, 2010). 
MDT can be calculated by the following equation: 
       MDT = (n/n+1). K-1/n          
 
 
2.10 Optimization of sustained release formulation of Ketorolac Tromethamine: 
 
Optimization is considered as an efficient and economical method to understand the 
relationship between independent and response variables (Bushra, Shoaib, Aslam, 
Hashmat, & Rahman, 2008). For the purpose of optimization, a 32 full factorial design 
comprising 9 full factorial design points was employed to systematically optimize drug 
release profile. During the experimental design, Methocel K100M CR (A) and Methocel 
K4M CR (B) were taken as the independent variables while the percentage of drug 
released after 1 hour (Y1hr), 4
 hours (Y4hr) and 8 hours (Y8hr) were considered as response 
variables. The relationship between responses and independent variables of all designed 
formulations were processed by Design Expert software. Statistical analysis was 
performed and contour plots were displayed to postulate the effects of the independent 
variables on responses followed by selection of the optimum formulation on the basis of 
desirability criterion and graphical analysis. 
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Result and Discussion 
3.1 Standardization of Ketorolac Tromethamine: 
The standardization of Ketorolac Tromethamine generated a linear calibration curve 
from the plot of absorbance versus concentration graph with a correlation coefficient 
(R2) of 0.9958 as shown in Figure 3.1. 
Table 3.1: Standardization of Ketorolac Tromethamine 
Concentration (mg/ml) Absorbance (λmax= 322 nm) 
0.0084 0.481 
0.00945 0.53 
0.0105 0.594 
0.01155 0.652 
0.0126 0.694 
 
 
Figure 3.1: Standard curve of Ketorolac Tromethamine 
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3.2 Evaluation of drug-excipient compatibility study: 
3.2.1 FT-IR characterization: 
 
Figure 3.2: Structure of Ketorolac Tromethamine 
 
Table 3.2: Principal functional groups of Ketorolac Tromethamine  
Functional group  Frequency (cm-1) 
                     Ketone  (C=O stretching) 1720-1705 
Aromatic ring (C=C stretching) 1600 and 1475 
Carboxylic acid (C=O stretching) 1725-1700 
                 Carboxylic acid (O-H stretching) 3400-2400 
Amine (N-H stretching) 3500-3100 
Amine (C-N stretching) 1350-1000 
Source: Pavia, Lampman, Kriz, & Vyvyan, 2008 
 
The principal peaks of Ketorolac Tromethamine were observed at 3349.50cm-1 for N-H 
stretching of primary amine; 3079.46 cm-1 for O–H stretching of alcohol; 1594.22 cm-1 
and 2898.14 cm-1 for C=O and O–H stretching of carboxylic acid respectively; 
1471.74cm-1 for C=C stretching of aromatic ring and 1385.9cm-1 for C-N stretching 
(Table 3.2). IR studies showed no interaction between drug and excipients selected for 
the study. However, additional peaks were observed in the spectrum of physical mixtures 
of drug and excipients but with no significant change in the original peak position and 
indicated that there was no chemical interaction between Ketorolac Tromethamine and 
other excipients. The spectra of the pure drug and drug-excipients are given in Figure 3.3 
to Figure 3.9. 
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Figure 3.3: FT-IR spectrum of Ketorolac Tromethamine (pure drug) 
 
 
Figure 3.4: FT-IR spectrum of Ketorolac Tromethamine + Methocel K100M CR 
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Figure 3.5: FT-IR spectrum of Ketorolac Tromethamine + Methocel K4M CR 
 
 
Figure 3.6: FT-IR spectrum of Ketorolac Tromethamine + Starch 1500 
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Figure 3.7: FT-IR spectrum of Ketorolac Tromethamine + Avicel PH 101 
 
 
Figure 3.8: FT-IR spectrum of Ketorolac Tromethamine + Talc 
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Figure 3.9: FT-IR spectrum of Ketorolac Tromethamine + Magnesium stearate 
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3.2.2 DSC characterization: 
The careful selection of excipients plays a significant role in the successful formulation 
of a stable and effective dosage form. DSC is an effective method to identify any 
physicochemical interaction between the ingredients used in the formulation and is 
therefore, widely used for the selection of suitable chemically compatible excipients. The 
absence of incompatibility between the drug and the excipients is seen when the 
thermograms of mixtures show patterns corresponding to the individual components. In 
contrast, any interaction may be indicated by the appearance or elimination of one or 
more new peaks when compared with the thermogram obtained from pure drug 
(Nanjwade, Manjappa, Murthy, & Pol, 2009). 
The DSC thermograms of KT showed long and sharp characteristic endothermic peak at 
165.98oC associated with the melting of KT (Figure 3.10). DSC scans of physical 
mixtures also showed characteristic endothermic peak corresponding to the pure drug 
which have been presented in Figure 3.11 to 3.16 respectively. These findings indicate 
that no interaction occurred between drug and the excipients which made it suitable for 
use in formulation of Ketorolac Tromethamine sustained release matrix tablet. However, 
there was a slight change in characteristic peak that may be due to fusion of excipients 
present in the physical mixture (Nanda, Saroha, & Sharma, 2014). 
 
Figure 3.10: DSC thermogram of Ketorolac Tromethamine (pure drug) 
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Figure 3.11: DSC thermogram of Ketorolac Tromethamine + Methocel K100M CR 
 
Figure 3.12: DSC thermogram of Ketorolac Tromethamine + Methocel K4M CR 
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Figure 3.13: DSC thermogram of Ketorolac Tromethamine + Starch 1500 
 
 
Figure 3.14: DSC thermogram of Ketorolac Tromethamine + Avicel PH 101 
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Figure 3.15: DSC thermogram of Ketorolac Tromethamine + Talc 
 
Figure 3.16: DSC thermogram of Ketorolac Tromethamine + Magnesium stearate 
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3.3 Evaluation of powder flow properties: 
In this experimental study, an attempt has been taken to develop “once daily” sustained 
release tablet of Ketorolac Tromethamine by direct compression method using two 
different viscosity grades of cellulose derivatives i.e. Methocel K100M CR and Methocel 
K4M CR as the rate retarding agents. According to the trial tablet formulations, powder 
blends of F1 to F9 were prepared and tested for powder flow properties. The powder 
blends of proposed formulations (F1 to F9) were evaluated for LBD, TBD, Carr‟s index, 
Hausner ratio and angle of repose as shown in Table 3.3. The results of LBD and TBD 
ranged from 0.339 ± 0.006 to 0.356 ± 0.011 (gm/ml) and 0.431 ± 0.005 to 0.460 ± 0.005 
(gm/ml) respectively. The results of Carr‟s compressibility index ranged from 18.56 ± 
2.36 to 24.00 ± 1.82 (%) with Hausner ratio between 1.27 ± 0.007 and 1.32 ± 0.04. The 
results of angle of repose ranged from 42.19 ± 0.085 to 45.47 ± 0.230 (°). All these 
results indicated that the powder possessed fairly good flow and compressibility 
properties. 
Table 3.3: Factors determining powder flow characteristics (F1 to F9) 
Formulation Loose bulk 
density 
(gm/ml) 
± SD 
Tapped 
bulk 
density 
(gm/ml) 
± SD 
Carr’s 
index (%) 
± SD 
Hausner 
Ratio 
± SD 
Angle of 
repose (º) 
± SD 
 
F1 0.356±0.011 0.460±0.005 22.61±1.55 1.29±0.03 42.19±0.085 
F2 0.342±0.003 0.450±0.015 24.00±1.82 1.32±0.04 42.51±0.205 
F3 0.351±0.007 0.445±0.01 21.12±3.24 1.27±0.06 43.44±0.06 
F4 0.351±0.006 0.445±0.01 21.12±0.425 1.27±0.007 42.49±0.159 
F5 0.351±0.007 0.431±0.005 18.56±2.36 1.23±0.04 42.52±0.415 
F6 0.339±0.006 0.445±0.01 23.82±0.36 1.31±0.007 43.44±0.06 
F7 0.350±0.005 0.450±0.006 22.22±2.07 1.29±0.04 45.47±0.230 
F8 0.351±0.006 0.445±0.01 21.12±0.425 1.27±0.007 42.65±0.280 
F9 0.339±0.006 0.440±0.004 22.95±1.64 1.30±0.03 44.72±0.185 
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3.4 Evaluation of physical properties of matrix tablets: 
The tablets of the proposed formulations (F1 to F9) were subjected to various evaluation 
tests like thickness, diameter, hardness, weight variation, friability and drug content as 
shown in Table 3.4. The hardness was found to be uniform in all tablets and percentage 
friability of the tablets of all the formulations was below 1% indicating that the friability 
was within the official limits. The average percentage weight variation and the drug 
content of tablets were found to be within pharmacopoeial limits. 
 
Table 3.4: Physical properties of matrix tablets (F1 to F9) 
Formulation Average weight 
(mg) ± SD 
Diameter 
(mm) 
Thickness 
(mm) ± SD 
Hardness 
(kg/cm2) 
Friability 
(%) 
Potency (%) ± 
SD 
F1 307±0.8  
 
 
9 
5.28±0.03  
 
 
7 
0.33 98.39±0.003 
F2 304.67±1.75 5.20±0.03 0.15 101.32±0.003 
F3 308.33±0.14 5.85±0.05 0.16 100.66±0.0008 
F4 309.33±1.22 5.47±0.04 0.17 101.98±0.001 
F5 306.33±0.80 5.15±0.06 0.16 102.64±0.003 
F6 302.33±0.81 5.15±0.06 0.67 98.39±0.004 
F7 308±0.65 5.72±0.04 0.32 101.98±0.002 
F8 308±0.65 5.65±0.04 0.16 99.43±0.004 
F9 307.33±0.14 5.68±0.04 0.49 102.53±0.003 
 
3.5 Drug release kinetic studies of Ketorolac Tromethamine matrix tablets: 
A polymer‟s ability to retard the drug release primarily depends on its viscosity and other 
processing factors like particle size, hardness, compressibility index, etc. Hence, 
Methocel K100M CR and Methocel K4M CR were used because it forms a strong 
viscous gel in contact with aqueous media, which may be useful in controlling delivery 
of drugs (Kabir, Halder, Shuma, & Rauf, 2012). The drug release data (Table 3.5 to 3.9) 
obtained from dissolution study was extrapolated by zero order, first order, Higuchi, 
Korsmeyer-Peppas and Hixson-Crowell equations to know the drug release kinetics 
followed by the nine formulations (Figure 3.17 to 3.21). 
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3.5.1 Zero order plot: 
Table 3.5: Zero order release profile of nine formulations of matrix tablets  
Time 
(hour) 
Cumulative % of drug released ± SD 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 14.90±
1.27 
 
17.96±
0.21 
 
15.71±
0.028 
 
14.75± 
0.50 
 
15.95±
1.29 
 
15.29± 
1.15 
 
13.25± 
0.07 
 
13.13± 
0.63 
15.06± 
0.48 
 
1 23.40±
0.72 
 
22.59±
0.30 
 
23.05±
0.45 
 
23.53± 
0.14 
 
29.76± 
5.78 
 
22.30± 
0.19 
 
21.15± 
1.48 
 
22.50± 
1.29 
 
24.54± 
1.89 
 
2 36.62±
0.59 
 
37.29±
1.61 
 
35.02±
0.75 
 
35.71± 
0.70 
 
38.39± 
0.24 
 
35.18± 
1.77 
 
31.31± 
0.52 
 
33.82± 
0.64 
 
31.23± 
0.40 
 
4 56.91±
0.56 
 
57.25±
0.23 
 
54.39±
1.45 
 
54.15± 
0.31 
 
57.83± 
1.07 
 
47.71± 
2.31 
 
50.28± 
0.54 
 
52.07± 
1.90 
 
58.24± 
0.62 
 
8 77.59±
1.17 
 
80.66±
0.25 
 
75.55±
1.25 
 
77.37± 
0.48 
 
73.28± 
1.27 
 
65.67± 
3.47 
 
71.34± 
1.53 
 
74.09± 
1.88 
 
77.76± 
1.72 
 
 
 
Figure 3.17: Zero order plot of release kinetics of Ketorolac Tromethamine matrix 
tablets 
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3.5.2 First order plot: 
Table 3.6: First order release profile of nine formulations of matrix tablets 
Time 
(hour) 
Log cumulative % of drug remaining 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
0.5 1.93 1.91 1.93 1.93 1.92 1.93 1.94 1.94 1.93 
1 1.88 1.89 1.89 1.88 1.85 1.89 1.90 1.89 1.88 
2 1.80 1.80 1.81 1.81 1.79 1.81 1.84 1.82 1.84 
4 1.63 1.63 1.66 1.66 1.63 1.72 1.70 1.68 1.62 
8 1.35 1.29 1.39 1.35 1.43 1.54 1.46 1.41 1.35 
 
 
Figure 3.18: First order plot of release kinetics of Ketorolac Tromethamine matrix 
tablets 
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3.5.3 Higuchi plot: 
Table 3.7: Higuchi release profile of nine formulations of matrix tablets 
Square 
root of 
time 
(hour) 
Cumulative % of drug released 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.71 14.90 
 
17.96 
 
15.71 
 
14.75 
 
15.95 
 
15.29 
 
13.25 
 
13.13 
 
15.06 
 
1 23.40 
 
22.59 
 
23.05 
 
23.53 
 
29.76 
 
22.30 
 
21.15 
 
22.50 
 
24.54 
 
1.41 36.62 
 
37.29 
 
35.02 
 
35.71 
 
38.39 
 
35.18 
 
31.31 
 
33.82 
 
31.23 
 
2 56.91 
 
57.25 
 
54.39 
 
54.15 
 
57.83 
 
47.71 
 
50.28 
 
52.07 
 
58.24 
 
2.83 77.59 
 
80.66 
 
75.55 
 
77.37 
 
73.28 
 
65.67 
 
71.34 
 
74.09 
 
77.76 
 
 
 
Figure 3.19: Higuchi plot of release kinetics of Ketorolac Tromethamine matrix 
tablets 
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3.5.4 Korsmeyer-Peppas plot: 
Table 3.8: Korsmeyer-Peppas release profile of nine formulations of matrix tablets 
Log of 
time 
(hour) 
Log fraction of drug released 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
-0.30 -0.83 -0.74 -0.80 -0.83 -0.80 -0.82 -0.88 -0.88 -0.82 
0 -0.63 -0.65 -0.64 -0.63 -0.53 -0.65 -0.67 -0.65 -0.61 
0.30 -0.44 -0.43 -0.46 -0.45 -0.42 -0.45 -0.50 -0.47 -0.51 
0.60 -0.24 -0.24 -0.26 -0.27 -0.24 -0.32 -0.30 -0.28 -0.23 
0.90 -0.11 -0.09 -0.12 -0.11 -0.14 -0.18 -0.15 -0.13 -0.11 
 
 
Figure 3.20: Korsmeyer-Peppas plot of release kinetics of Ketorolac Tromethamine 
matrix tablets 
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3.5.5 Hixson-Crowell plot: 
Table 3.9: Hixson-Crowell release profile of nine formulations of matrix tablets 
Time 
(hour) 
 
Cubic root of total amount of drug (%) - Cubic root of drug remaining (%) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 0.24 0.30 0.26 0.24 0.26 0.25 0.21 0.21 0.24 
1 0.39 0.38 0.39 0.40 0.52 0.37 0.35 0.38 0.42 
2 0.65 0.67 0.62 0.64 0.69 0.62 0.55 0.60 0.54 
4 1.14 1.14 1.07 1.06 1.16 0.76 0.96 1.01 1.17 
8 1.82 1.96 1.74 1.81 1.65 1.39 1.58 1.68 1.83 
 
 
Figure 3.21: Hixson-Crowell plot of release kinetics of Ketorolac Tromethamine 
matrix tablets 
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3.6 Interpretation of release rate constants and R2 values for different formulations: 
The release constant was calculated from the slope of the appropriate plots, and the 
regression coefficient (R2) was determined (Table 3.10). In this experiment, the in vitro 
release kinetics of drug could be best expressed by Higuchi model (R2: 0.984 to 0.997) as 
the relevant plot showed high linearity for most of the formulations, followed by first 
order model (R2: 0.968 to 0.996) and Hixson-Crowell model (R2: 0.939 to 0.987) as 
shown in Table 3.10. It was clearly evident that the formulations did not follow zero 
order release pattern because the R2 value did not show relatively high linearity. To 
confirm the drug release mechanism from the matrix tablets, the data were fitted into 
Korsmeyer-Peppas equation which is often used to describe the drug release behavior 
from the polymeric systems. When plotted according to Korsmeyer-Peppas equation, the 
formulations F1, F3, F4, F6, F7 and F8 showed high linearity (R2 >= 0.995), with  slope 
(n) values between 0.537 and 0.623 (Table 3.11), which appears to indicate that diffusion 
as well as erosion was the predominant mechanism of drug release for the tablets.  
Hence, diffusion coupled with erosion might be the proposed mechanism for the release 
of drug from Methocel K100M and Methocel K4M based sustained release matrix tablet 
of Ketorolac Tromethamine. 
  Table 3.10: Drug release rate constants and R2 values for different formulations 
Formulation Zero order First order Higuchi Korsmeyer- 
Peppas 
Hixson-
Crowell 
K0 R
2 K R
2 Kh R
2 n R2 KHC R
2 
F1 9.101 0.951 0.183 0.994 28.492 0.993 0.610 0.995 0.221 0.979 
F2 9.358 0.932 0.198 0.996 29.154 0.994 0.570 0.987 0.235 0.987 
F3 8.773 0.927 0.171 0.994 27.427 0.996 0.580 0.998 0.208 0.980 
F4 9.002 0.933 0.181 0.996 28.045 0.995 0.600 0.998 0.217 0.985 
F5 8.320 0.867 0.157 0.968 26.796 0.988 0.537 0.970 0.195 0.939 
F6 7.424 0.896 0.125 0.970 23.630 0.997 0.537 0.993 0.158 0.956 
F7 8.368 0.939 0.151 0.995 25.958 0.993 0.610 0.997 0.190 0.983 
F8 8.679 0.934 0.165 0.995 27.004 0.994 0.623 0.995 0.202 0.982 
F9 9.186 0.927 0.185 0.990 28.538 0.984 0.600 0.982 0.223 0.978 
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Table 3.11: The best fitted model and drug release mechanism followed by the 
matrix tablets of Ketorolac Tromethamine 
Formulation Best fitted model n value 
(Korsmeyer- 
Peppas model) 
Release 
mechanism 
F1 Korsmeyer-Peppas, 
First order, Higuchi, 
Hixson-Crowell and 
Zero order 
0.610 Anomalous/Non- 
Fickian Release 
F2 First order, Higuchi, 
Korsmeyer-Peppas, 
Hixson-Crowell and 
Zero order 
0.570 Anomalous/Non- 
Fickian Release 
 
 
F3 Korsmeyer-Peppas, 
Higuchi, First order, 
Hixson-Crowell and 
Zero order 
0.580 Anomalous/Non- 
Fickian Release 
F4 Korsmeyer-Peppas, 
First order, 
Higuchi, Hixson-
Crowell and Zero 
order 
0.600 Anomalous/Non- 
Fickian Release 
F5 Higuchi, Korsmeyer-
Peppas, First order 
and Hixson-Crowell 
0.537 Anomalous/Non- 
Fickian Release 
F6 Higuchi, Korsmeyer-
Peppas, First order 
and  Hixson-Crowell 
0.537 Anomalous/Non- 
Fickian Release 
F7 Korsmeyer-Peppas, 
First order, 
Higuchi, Hixson-
Crowell and 
Zero order 
0.610 Anomalous/Non- 
Fickian Release 
F8 Korsmeyer-Peppas, 
First order, 
Higuchi, Hixson-
Crowell and 
Zero order 
0.623 Anomalous/Non- 
Fickian Release 
F9 First order, Higuchi, 
Korsmeyer- Peppas, 
Hixson-Crowell and 
Zero order 
0.600 Anomalous/Non- 
Fickian Release 
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3.7 Analysis of successive fractional dissolution time: 
Successive fractional dissolution time and MDT of the nine formulations (F1 to F9) of 
Ketorolac Tromethamine matrix tablets are mentioned in Table 3.12 and depicted in 
Figure 3.22. The T25%, T50%, T80% and MDT values showed very little increase in the drug 
retaining ability of the polymers for some formulations. The time taken to release 25%, 
50% and 80% of the drug from the matrix tablet was found to increase with rise in 
amount of Methocel K4M CR for F1 to F3 and F4 to F6 respectively thereby reflecting 
retardation of drug release rate and hence higher MDT value as the concentration of the 
polymer increased. However, the formulations F7 to F9 showed slight deviation from the 
general phenomena of retarding capacity with increase in polymer loading. Similarly, 
T25%, T50%, T80% and MDT for F1, F4, F7 and F2, F5, F8 were found to increase with the 
rise in loading of Methocel K100M CR although a deviation was observed for F9 when 
compared with values of F3 and F6. 
 
Table 3.12: Successive fractional dissolution time of nine formulations of Ketorolac 
Tromethamine matrix tablets 
Formulation T25% (hour) T50%(hour) T80%(hour) MDT (hour) 
F1  1.124 3.501 7.565 4.132 
F2  0.996 3.359 7.662 4.115 
F3 1.117 3.691 8.301 4.477 
F4 1.148 3.644 7.976 4.339 
F5  0.937 3.411 8.188 4.334 
F6  1.202 4.374 10.501 5.558 
F7  1.357 4.228 9.137 4.991 
F8  1.281 3.894 8.276 4.546 
F9 1.139 3.616 7.916 4.306 
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Figure 3.22: Comparison of MDT, T25%, T50%, T80% values of different formulations 
 
3.8 Optimization of formulation using 32 full factorial design: 
3.8.1 Summary of the design: 
The optimization of the formulation was carried out using 32 full factorial design by 
means of Design Expert software where Factor 1 and Factor 2, represented by Methocel 
K100M CR (A) and Methocel K4M CR (B) respectively were taken as two independent 
variables. The levels were set as low (-1), medium (0) and high (1) followed by input of 
in vitro drug release data to analyze the extent of dependence of drug release on the 
polymers after 1, 4 and 8 hours (Figure 3.23 and 3.24).  
 
Figure 3.23: The actual design of the experiment 
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Figure 3.24: Summary of the design 
3.8.1.1 Graph column: 
The graph column determines the correlation between the individual polymer content 
and release of the drug after 1, 4 and 8 hours. Figure 3.25 to 3.27 shows plot of Factor 1 
(Methocel K100M CR) versus response after 1, 4 and 8 hours which depicted that the 
polymer loading is weakly correlated with the release of the drug at low, mid and high 
level because the increase in amount of Methocel K100M CR do not show significant 
control on drug release of some formulations. In contrast, the graph of Factor 2 
(Methocel K4M CR) against response after 1, 4 and 8 hours showed better influence of 
polymer loading compared to Factor 1 at all levels (Figure 3.28 to 3.30). 
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Figure 3.25: The graph column of Methocel K100M CR (A) after 1 hour 
 
 
Figure 3.26: The graph column of Methocel K100M CR (A) after 4 hours 
 
Result and Discussion 
43 
 
 
Figure 3.27: The graph column of Methocel K100M CR (A) after 8 hours 
 
 
Figure 3.28: The graph column of Methocel K4M CR (B) after 1 hour 
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Figure 3.29: The graph column of Methocel K4M CR (B) after 4 hours 
 
 
Figure 3.30: The graph column of Methocel K4M CR (B) after 8 hours 
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3.8.2 Analysis of the full factorial design: 
A statistical model incorporating interactive and polynomial terms was used to evaluate 
the responses as represented by the following equation:  
         Y= b0 + b1A + b2B + b3AB + b4A
2 + b5B
2 
where,  
          Y is the dependent variable,  
          A, B are the coded levels of the independent variable, 
          b0 is the intercept representing the arithmetic mean response of the 9 runs,  
          b1 to b5 are the estimated coefficients computed from the observed experimental 
response values of Y. 
The main effects (A and B: Linear) represent the average result of changing one factor at 
a time from its low to high values. The interaction terms (AB: 2 FI) show how the 
response changes when two factors are simultaneously changed. The polynomial terms 
(A2 and B2: Quadratic) are included to investigate nonlinearity of the model.  
 
 
3.8.2.1 Response after 1 hour: 
After 1 hour, for each source of terms (intercept, A, B, AB, A2, B2), the probability value 
(p-value) was examined to choose the statistical model that best evaluates the response. 
So far, the Design Expert software predicted that the release pattern after 1 hour (Y1hr) 
followed a quadratic model as the p-value for this model was found to be lower i.e. 
0.1796 relative to linear, 2 FI and cubic models (Figure 3.31). Similarly, lack of fit test 
and model summary statistics displayed by the software suggested less lack of fitness for 
the quadratic model as it exhibits low standard deviation (Std. Dev), high “R-Squared” 
value and a low “PRESS” (Figure 3.32). 
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Figure 3.31: Suggested statistical model for response after 1 hour 
 
 
Figure 3.32: Fit summary report for response after 1 hour 
 
The response after 1 hour was also statistically analyzed by analysis of variance 
(ANOVA) at the 5% significance level. From the ANOVA for response surface 
quadratic model, the ability of the model to provide adequate information on the 
dependence of drug release on polymer was determined. The p-value for the model was 
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found to be 0.4464 (p>0.05) indicating that the model is not significant and the chance of 
error is more than 5% (Figure 3.33). 
 
 
Figure 3.33: ANOVA statistics for response after 1 hour 
 
The polynomial equation represents the quantitative effect of factors (A and B) upon the 
response. Coefficients with one factor (A or B) represent the effect of that particular 
factor while the coefficients with more than one factor (AB) and those with second order 
terms (A2 and B2) represents the interaction between those factors and the quadratic 
nature of the model respectively. A positive sign in front of the terms indicates 
accelerating effects while the negative sign indicates retarding effects of the factor. 
 
The predicted equation for Y1hr in terms of coded factors is mentioned below:  
Y1hr = 27.66 - 0.14A + 0.30B + 0.94AB - 3.02A
2 - 2.65B2 
According to the above equation, coefficient b1 bears a negative sign which means that 
„A‟ decreased the response by 0.14 times. So increasing the amount of the Methocel 
K100M CR polymer in the formulations increased the time taken by the drug to leave the 
formulation and retarded release of drug into the medium. Coefficient b2 bear positive 
sign indicating that „B‟ increased the response by 0.3 times. Moreover, combination of A 
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and B increased the drug release by 0.94 times. Therefore, both „A‟ and „B‟ were 
responsible for the response after 1 hour but „A‟ participated in the retarding effect of the 
polymer. 
The quadratic model generated for Y1hr was used to construct two dimensional (2D) 
contour plot and three dimensional (3D) surface response plot in which the response 
parameter was represented by a curvature surface as a function of „A‟ and „B.‟ The 2D 
contour plot as well as the 3D response surface plot in Figure 3.34A and 3.34B shows 
the effect of polymer on drug release after 1 hour.  
 
 
Figure 3.34A: 2D contour plot of drug release after 1 hour 
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Figure 3.34B: 3D surface plot of drug release after 1 hour 
The diagnostic--normal plot of residuals determines the linearity of the data points and 
for the 1st hour, the practical response values for all the formulations were found in close 
proximity with the theoretical values, thereby, showing linearity (Figure 3.35). 
 
Figure 3.35: Normal plot of residuals after 1 hour 
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3.8.2.2 Response after 4 hours: 
For the response after 4 hours (Y4hr), only b0 with a value of 54.67 was obtained 
indicating that the polymer has no control on the release of drug after 4 hours. The 
contour and surface plots also supported the statistical model which showed that the 
release was independent of the polymer loading (Figure 3.36A and 3.36B). The normal 
plot of residuals illustrated linear relationship between experimental and theoretical 
response data (Figure 3.37). 
 
 
Figure 3.36A: 2D contour plot of drug release after 4 hours 
 
Figure 3.36B: 3D surface plot of drug release after 4 hours 
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Figure 3.37: Normal plot of residuals after 4 hours 
 
3.8.2.3 Response after 8 hours: 
For the response after 8 hours (Y8hr), only b0 with a value of 74.66 was obtained 
indicating that the polymer has no control on the release of drug after 8 hours. The 
contour and surface plots also supported the statistical model which showed that the 
release was independent of the polymer loading (Figure 3.38A and 3.38B). The normal 
plot of residuals depicted linear relationship between experimental and theoretical 
response data (Figure 3.39). 
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Figure 3.38A: 2D contour plot of drug release after 8 hours 
 
 
Figure 3.38B: 3D surface plot of drug release after 8 hours 
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Figure 3.39: Normal plot of residuals after 8 hours 
 
 
Figure 3.40: Summary of the responses after 1, 4 and 8 hours 
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3.8.3 Optimization of the formulation: 
For optimization, a numerical technique was employed to generate formulation with 
desired responses. As a result, the desirable ranges of these responses were restricted to 
21%<Y1hr<25%, 45% <Y4hr<55% and 65% <Y8hr<75%. The optimum coded levels of 
each independent variable were based on the desirability criterion and graphical analysis. 
An overlay plot was obtained that displayed a yellow region for the possible optimum 
formulations (Figure 3.41). 
 
 
Figure 3.41: The overlay plot of the optimization area 
The optimum formulation was chosen to be F4, primarily on the basis of desirability 
criterion and graphical analysis of the formulation (Figure 3.42 and 3.43) where the 
observed responses were found to be in close agreement with the predicted values for the 
optimized formulation (Table 3.13). Moreover, T25% was also considered as a parameter 
for the selection because the time taken to release 25% of drug was 1.148 hour (Table 
3.12). The Korsmeyer-Peppas model also showed significant R2 value for F4 (Table 
3.10). The physical parameters evaluated for F4 were also found to be satisfactory and 
within the specifications (Table 3.3 and 3.4). 
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Figure 3.42: Optimum formulation with predicted drug release profile 
 
Figure 3.43: The overlay plot of the optimum formulation 
 
 
 
 
 
 
Result and Discussion 
56 
 
Table 3.13: Composition of the optimum formulation with the predicted and 
experimental values of response variables 
Composition 
Methocel K100M 
CR: Methocel 
K4M CR 
Response 
variables 
Experimental 
value (%) 
Predicted 
value (%) 
 
Prediction 
error (%) 
F4= 35:5 Drug release 
after 1 hour 
23.53 24.709 3.56 
Drug release 
after 4 hours 
54.15 54.666 3.82 
Drug release 
after 8 hours 
77.37 74.659 4.40 
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Conclusion 
In the present study, a sustained release oral tablet dosage form of Ketorolac 
Tromethamine was successfully formulated. The design of this experiment involved the 
formulation of nine trial batches of the matrix tablet using different ratio of hydrophilic 
polymers for each. All the components of the formulation showed compatibility with 
each other and the physical parameters of the tablets were found to comply with the 
specifications. In vitro dissolution study of the tablets performed for eight hours 
generated drug release profile for the nine formulations, which were fitted into several 
mathematical models to identify the release kinetics and drug transport mechanism that 
is followed by the matrix tablets. Finally, optimization of the formulation was carried out 
by using Design Expert software and hence, a once daily oral sustained release tablet 
formulation was obtained. 
 
Recommendation 
Due to time constraint, further trial batches with different polymer combinations could 
not be investigated. Thus, this leaves behind a scope to carry out extensive work on the 
formulations.  
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Appendix 
Appendix 1 
Ketorolac Tromethamine 
Ketorolac Tromethamine is a tromethamine salt of Ketorolac which enhances the 
solubility of Ketorolac to help in absorption. It is a member of non-steroidal anti-
inflammatory drug (NSAID) and is indicated for the short-term management of moderate 
to severe pain, especially post-operative pain. Ketorolac Tromethamine is rapidly 
absorbed and hence exhibit bioavailability of 80% to 100%. More than 99% of the drug 
in plasma is protein bound over a wide concentration range. It is metabolized in the liver 
via glucuronidation and para-hydroxylation followed by approximately 90% of the drug 
elimination in urine, and around 6% to 8% in the feces. 
 
Chemical Name: (±)-5-Benzoyl-2,3-dihydro-1Hpyrrolizine-1-carboxylic acid, 2-amino-
2-(hydroxymethyl)-1,3-propanediol 
Molecular formula: C19H24N2O6 
Molecular weight: 376.40 g/mol 
Melting point: 162°C 
Appearance: White or off-white crystalline powder 
BCS classification: Class I accompanied by high solubility and high permeability 
Solubility: Freely soluble in water and methanol, slightly soluble in ethanol and 
practically insoluble in acetone, methylene chloride and toluene 
pKa: 3.46 
pH: The pH of a 1% (w/v) solution in distilled water is 5.7-6.7 (Vadivelu et al., 2015). 
 
Dosage and administration: 
Ketorolac Tromethamine tablets are indicated only as continuation therapy to Ketorolac 
Tromethamine injection, and the combined duration of use of Ketorolac Tromethamine 
injection and Ketorolac Tromethamine tablets should not exceed 5 days, because of the 
increased risk of serious adverse events. The recommended dosage regimen is 10mg 
every four to six hours and should not exceed 40 mg per day (Roche, 2008).
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Appendix 2 
Ultraviolet-Visible spectrophotometry  
UV-Visible spectrophotometry is one of the most frequently employed techniques in 
pharmaceutical analysis. It involves measuring the amount of ultraviolet or visible 
radiation absorbed by a substance in solution. Instrument which measures the ratio, or 
function of ratio, of the intensity of the incident and transmitted beams of light in the 
UV-Visible region is called UV-Visible spectrophotometer. In qualitative analysis, 
organic compounds can be identified by the use of spectrophotometer, if any recorded 
data is available, and quantitative spectrophotometric analysis is used to ascertain the 
quantity of molecular species absorbing the radiation. Spectrophotometric technique is 
simple, rapid, moderately specific and applicable to small quantities of compounds. The 
fundamental law that governs the quantitative spectrophotometric analysis is the Beer-
Lambert law.  
Beer‟s law: It states that the intensity of a beam of parallel monochromatic radiation 
decreases exponentially with the number of absorbing molecules. In other words, 
absorbance is proportional to the concentration. 
Lambert‟s law: It states that the intensity of a beam of parallel monochromatic radiation 
decreases exponentially as it passes through a medium of homogeneous thickness.  
A combination of these two laws yields the Beer - Lambert law. 
Beer-Lambert law: When beam of light is passed through a transparent cell containing a 
solution of absorbing substance, reduction of the intensity of light may occur. 
Mathematically, Beer - Lambert law is expressed as 
A = a b c 
Where, A = absorbance  
             a = absorptivity or extinction coefficient 
             b = path length of radiation through sample  
             c = concentration of solute in solution. 
Both „a‟ and „b‟ are constant, so „A‟ is directly proportional to the concentration „c‟ 
(Behera, Ghanty, Ahmad, Santra, & Banerjee, 2012). 
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Appendix 3 
FT-IR 
FT-IR or Fourier Transform Infrared spectroscopy is the study of the interaction of 
electromagnetic radiation from the IR region of the EM spectrum (4000-400) cm-1 with a 
molecule through which IR radiation is passed. The nature of interaction depends upon 
the functional groups present into the substance. When IR radiation passed through a 
sample (solid, liquid or gas), certain frequencies of the radiation are absorbed by the 
atoms of the substance leading to molecular vibration. The frequencies of absorbed 
radiation are unique for each atom or group of atom, which provide the characteristics of 
bonds associated with a substance. The resulting IR spectrum represents the molecular 
absorption and transmission, which can be divided into two approximate regions: 
 Functional group region (4000-1500 cm-1), valuable information are obtained from 
this region to interpret any spectrum. 
 Fingerprint region (<1500 cm-1), usually consists of a very complicated series of 
absorption that are characteristic for a particular compound. Like a fingerprint no two 
unique molecular structures produce the same infrared spectrum. 
As the frequency of vibration of a bond in a molecule depends on the nature of the atoms 
joined by the bond, arrangement of atoms within the molecule (i.e. environment), mass 
of the atom and strength of the bonds, no two molecule of different structure have 
exactly the same infrared spectrum. For this reason, the Infrared spectrum can be used 
for molecules much as a fingerprint can be used for humans (Pavia, Lampman, Kriz, & 
Vyvyan, 2008; Mubtasim, Kabir, Podder, & Bhadra, 2015). 
 
Figure: Schematic diagram of FT-IR spectrometer
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Appendix 4 
DSC 
Differential Scanning Calorimetry, or DSC, is a thermal analysis technique that looks at 
how a material‟s heat capacity (Cp) is changed by temperature. A sample of known mass 
is heated or cooled and the changes in its heat capacity are tracked as changes in the heat 
flow. This allows the detection of transitions such as melts, glass transitions, phase 
change, and curing. Because of this flexibility, since most materials exhibit some sort of 
transitions, DSC is used in many industries, including pharmaceuticals, polymers, food, 
paper, printing, manufacturing, agriculture, semiconductors, and electronics. The biggest 
advantage of DSC is the ease and speed with which it can be used to see transitions in 
materials (Satpute & Sayed, 2015). 
 
Figure: Schematic diagram of the interior of a DSC 
 
Appendix 5 
Dissolution 
Dissolution test is required to evaluate the release of drug from a pharmaceutical dosage 
form as a predictor of the in vivo performance of a drug product. A dissolution test is a 
simple concept, where a tablet or capsule is placed into a known volume of media and as 
it dissolves the resulting solution is sampled over time, and assayed (often by HPLC or 
by spectrophotometry) for the level of active pharmaceutical ingredient (API) present. 
The choice of apparatus is also a matter of consideration during the method development 
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which is based on the dosage form performance in the in vitro test system (Vaghela, 
Kayastha, Bhatt, Pathak, & Rathod, 2011). 
 
Figure: Dissolution apparatus 
Dissolution is evaluated by measuring rate release profile or the amount dissolved over 
time. So, duration is another important criteria need to be considered during the method 
development of dissolution. For immediate release dosage forms, the procedure duration 
is usually 30 to 60 minutes and in most cases, single time point specification is adequate. 
On the other hand, for extended release dosage forms, at least three test time points are 
typically chosen to characterize the in vitro drug release profile (Vaghela, Kayastha, 
Bhatt, Pathak, & Rathod, 2011). At last, for analyzing the dissolution test samples, 
spectrophotometric (UV) determinations and HPLC are most commonly used. When a 
method is developed for particular testing of any specific dosage form, that method 
needs to be validated for the consistency of the results for further conductance of the 
process. 
 
Appendix 6  
Hydrophilic Matrix Systems 
 
Hydrophilic matrix systems are among the most commonly used means for oral 
controlled drug delivery as they can reproduce a desirable drug release profile and are 
cost effective. Hydroxypropyl methylcellulose (HPMC), also known as Hypromellose 
according to USP or Methocel designated by Dow Company, provides the release of a
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drug in a controlled manner, effectively increasing the duration of release of a drug to 
prolong its therapeutic effect (Phadtare, Phadtare, Nilesh, & Asawat, 2014). To achieve 
controlled release through the use of a water-soluble polymer such as Hypromellose, the 
polymer must quickly hydrate on the outer tablet surface to form a gelatinous layer. A 
rapid formation of a gelatinous layer is critical to prevent wetting of the interior and 
disintegration of the tablet core. Once the original protective gel layer is formed, it 
controls the penetration of additional water into the tablet. As the outer gel layer fully 
hydrates and dissolves, a new inner layer must replace it and be cohesive and continuous 
enough to retard the influx of water and control drug diffusion. Although gel strength is 
controlled by polymer viscosity and concentration, polymer chemistry also plays a 
significant role (Varma, Kaushal, Garg, & Garg, 2004).  
 
Table: Typical properties of selected Methocel K100M CR and Methocel K4M CR 
grade products 
Methocel product 
grade 
Methoxyl (%) Hydroxypropoxyl 
(%) 
Apparent 
viscosity, 2% in 
water at 20°C (cP) 
K100M CR 19-24 4-12 80000-120000 
K4M CR 19-24 4-12 3000-5600 
Source: Siepmann & Peppas, 2001 
Factors affecting the kinetics and mechanism of drug release from the matrix 
tablet: 
Drug characteristics: Drug solubility, dose/drug content, molecular weight and size, 
particle size and shape. 
Polymer variables: Polymer type, polymer viscosity grade, polymer proportion, particle 
properties, polymer combinations. 
Formulation aspects: Formulation geometry, processing technique, excipients/additives 
(Varma, Kaushal, Garg, & Garg, 2004). 
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